Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

African Union backs call to waive intellectual property rights on COVID-19 drugs

Published 02/25/2021, 07:00 AM
Updated 02/25/2021, 09:00 AM
© Reuters. FILE PHOTO: John Nkengasong, Africa's Director of the Centers for Disease Control, speaks during an interview with Reuters at the African Union Headquarters in Addis Ababa

JOHANNESBURG (Reuters) - The African Union is backing calls for drugmakers to waive some intellectual property rights on COVID-19 medicines and vaccines to speed up their rollout to poor countries, the head of its disease control body said on Thursday.

South Africa and India, which both manufacture drugs and vaccines, made the proposal at the World Trade Organization last year, saying intellectual property (IP) rules were hindering the urgent scale-up of vaccine production and provision of medical products to some patients.

They have faced opposition from some developed nations, but the backing of the African Union may give renewed impetus for the push to relax IP rules.

John Nkengasong, director of the Africa Centers for Disease Control and Prevention, told a news conference IP transfers were a "win-win for everybody" that would address huge inequalities in global public health.

He gave two examples where the developing world had suffered from restricted access to medicines: the swine flu pandemic in the late 2000s and HIV/AIDS in the 1990s.

"In 1996, HIV drugs were available, and we saw how mortality in the developed world decreased drastically. But it would take 10 years before those drugs were accessible in Africa in any meaningful way," he said.

"In between, 12 million Africans died, so I just use those numbers to say: any IP transfer will be beneficial to everybody, because nobody wants to sit back and be proud of that sad event. ... We want to be on the right side of history."

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Separately, the WHO's Africa director Matshidiso Moeti urged pharmaceutical companies to be flexible with their IP to facilitate access to medicines.

She expressed hope that discussions over waiving IP rights would "turn into action at some point in the future".

Nkengasong added the Africa CDC's regulatory taskforce had approved AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine for emergency use, a day after Ghana received its first AstraZeneca doses from global vaccine distribution facility COVAX.

He said the developers of Russia's Sputnik V vaccine had submitted data dossiers to the Africa CDC and an expert panel would review it.

"We have not received dossiers yet from China colleagues, but we remain optimistic," he added.

Egypt, Zimbabwe and Senegal have already started rolling out Chinese COVID-19 shots.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.